Publications by authors named "D Lauro"
Article Synopsis
- - Kallmann syndrome (KS) is a genetic disorder characterized by low reproductive hormone levels and loss of smell, caused by issues in the early development of certain neurons that regulate these functions, with some links to Waardenburg syndrome.
- - A case study of a 28-year-old woman with a lifelong KS diagnosis revealed hearing loss and skin pigmentation issues, and genetic testing identified a specific pathogenic variant that was also present in her mother, who displayed fewer symptoms.
- - The findings emphasize the diverse expressions of KS and related conditions, indicating that patients may show a wide range of symptoms and suggesting the importance of ongoing monitoring for potential additional traits.
The aim of the current study was to evaluate the outcomes of patients with diabetic foot osteomyelitis (DFO), comparing subjects with and without peripheral arterial disease (PAD). The study is a prospective study including a population of patients affected by a DFO located in the forefoot. All patients were managed by a surgical conservative approach defined by the removal of the infected bone, in association with the antibiotic therapy.
View Article and Find Full Text PDFNanomedicine could improve the treatment of diabetes by exploiting various therapeutic mechanisms through the use of suitable nanoformulations. For example, glucose-sensitive nanoparticles can release insulin in response to high glucose levels, mimicking the physiological release of insulin. Oral nanoformulations for insulin uptake via the gut represent a long-sought alternative to subcutaneous injections, which cause pain, discomfort, and possible local infection.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated apheresis practices in the US through a national survey involving 22 academic medical institutions to identify trends and challenges.
- The survey revealed that therapeutic plasma exchange (TPE) is the most common procedure, with issues in staffing exacerbated by COVID-19 affecting service delivery.
- Findings emphasized the importance of apheresis in cellular therapies and the need for innovative staffing solutions in the context of ongoing medical advancements and challenges.
Objective: Glucagon-like peptide-1 receptor agonists (GLP1RAs), originally developed for the treatment of type 2 diabetes mellitus, have attracted attention for their potential therapeutic benefits in asthma due to their anti-inflammatory properties and effects on airway smooth muscle function. However, concerns have been raised about the possibility of GLP1RAs inducing or exacerbating asthma symptoms.
Methods: We reviewed data from the US Food and Drug Administration's (FDA) adverse event (AE) reporting system (FAERS) to examine reports of cases of asthma observed in the real-world during treatment with GLP1RAs.